Original articleGeneral thoracicAdjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma
Section snippets
Patient Selection
From January 1998 to January 2003, 40 patients who underwent curative esophagectomy were prospectively enrolled in this study. Eligible criteria included (1) histologically proven squamous cell carcinoma of the thoracic esophagus; (2) curative R0 resection (no microscopic residual tumor); (3) transthoracic esophagectomy with radical lymphadenectomy such as cervico-thoracoabdominal three-field lymphadenectomy or thoracoabdominal total two-field lymphadenectomy; (4) a pathologic classification of
Patient Characteristics
During the period from January 1998 to January 2003, 40 consecutive patients were entered into the study. The clinical characteristics of the enrolled patients are provided in Table 1. The historical control group consisted of 52 patients. All patients in both arms had squamous cell carcinoma of esophagus and pathologically confirmed regional lymph node metastases (pN1). Both groups had similar pathologic characteristics in tumor status, location, histology, and differentiation. However, the
Comment
A high frequency of metastatic disease as the cause of death in resected esophageal cancer patients has resulted in intense exploration for the application of systemic therapy in the treatment of esophageal cancer. Recently, chemotherapy with or without other local modality of surgery or radiation has been introduced as neoadjuvant, definitive, or adjuvant settings; however, the confirmatory clinical trials showing survival advantages in any of these settings to date are lacking [10, 11, 12, 13
References (32)
- et al.
En bloc esophagectomy improves survival for Stage III esophageal cancer
J Thorac Cardiovasc Surg
(1997) - et al.
Proposed revision of the staging classification for esophageal cancer
J Thorac Cardiovasc Surg
(1998) - et al.
Tumors of the esophagogastric junctionlong term survival in relation to the lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification
J Thorac Cardiovasc Surg
(1996) - et al.
Chemotherapy for carcinoma of the esophagusa comparison of evidence from meta-analyses of randomized trials and of historical control studies
Ann Oncol
(1996) - et al.
Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus
J Thorac Cardiovasc Surg
(1988) - et al.
Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagusa prospective randomized trial
J Thorac Cardiovasc Surg
(1997) - et al.
A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer
Am J Surg
(2002) - et al.
A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagusThe Japan Clinical Oncology Group Study
J Thorac Cardiovasc Surg
(1997) - et al.
Surgical therapy of esophageal carcinoma
Br J Surg
(1990) - et al.
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
N Engl J Med
(1990)
A randomized trial of surgery alone vs surgery plus postoperative chemotherapy with cisplatin and 5-fluorouracil for localized squamous carcinoma of the thoracic esophagusthe Japan clinical oncology group study (JCOG9204)
Proc Am Soc Clin Oncol
Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagusa Japan Clinical Oncology Group Study-JCOG9204
J Clin Oncol
Reporting results of cancer treatment
Cancer
Nonparametric estimation from incomplete observations
J Am Stat Assoc
Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research
Surg Gynecol Obstet
Postoperative radiotherapy for carcinoma of the esophagusa prospective, randomized controlled study
Surgery
Cited by (59)
Consolidation Therapy in Esophageal Cancer
2021, Surgical Clinics of North AmericaPredicting prognosis in resected esophageal squamous cell carcinoma using a clinical nomogram and recursive partitioning analysis
2018, European Journal of Surgical OncologyCitation Excerpt :Besides, different surgery program would lead to disparate eradicative effect, which not only impact the long-term survival but also affect the significance of other factors [26,27]. For example, the positive role of adjuvant chemotherapy in expanding long-term survival was only observed in patients underwent left-transthoracic esophagectomy [4,6,9]. It is plausible that, when a clinical nomogram is developed based on a cohort with inhomogenous surgery, it might be biased for individual patient since the surgery program is identified [20–23].
Comparison of the 7th and proposed 8th editions of the AJCC/UICC TNM staging system for esophageal squamous cell carcinoma underwent radical surgery
2017, European Journal of Surgical OncologyCitation Excerpt :However, on the issue of effectiveness of adjuvant treatment in ESCC patients underwent radical surgery, controversy is still exist. Although some prospective and retrospective studies indicated positive effect of adjuvant treatment in prolonging disease-free survival in patients with nodal metastasis, there is not enough evidence to show that adjuvant treatment could expanded long-term survival in these patients.22–24 In this study, most of patients without nodal metastasis (83.5%, 616/738) does not received adjuvant treatment, which explains the better outcome of patients without adjuvant treatment; in patients with nodal metastasis, we fail to observe longer survival in those received adjuvant treatment (P = 0.897 by log-rank test).
Nodal Skip Metastasis in Esophageal Squamous Cell Carcinoma Patients Undergoing Three-Field Lymphadenectomy
2017, Annals of Thoracic SurgeryCitation Excerpt :Patients with and without NSM were matched using a Propensity Score Matching (PSM) method according to Rosenbaum and Rubin [10]. The propensity score for an individual was calculated based on a multivariable logistic regression model with the covariates of well-known prognostic factors, including age, sex, pathologic T status, pathologic N status, and adjuvant treatment [3, 5, 11]. According to the propensity scores, patients without NSM were individually matched to patients with NSM using a computerized technique of nearest available score matching.
Advances in the Theranostics of Oesophageal Squamous Carcinoma
2023, Advanced Therapeutics
- ⁎
These authors contributed equally to the article.